Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Z-Val-Ala-Asp fluoromethyl ketone (commonly abbreviated as Z-VAD-FMK) is a synthetic small molecule that acts as a non-methylated, competitive, and irreversible inhibitor of caspase 1 (also known as interleukin 1 beta-converting enzyme or ICE), as well as other caspases. It is widely used in research to inhibit apoptosis by blocking the activity of caspases, which are key mediators of programmed cell death. Unlike some related compounds, it does not require an esterase for activation and can be used directly with purified enzymes. It is considered a pan-caspase inhibitor due to its broad activity against multiple caspase family members. Its primary use is experimental and investigational; it has not been approved for clinical use in humans[2][3][4][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on z-val-ala-asp fluoromethyl ketone.